Реакция #709618

ord-9561b47bc70946deaf0118774fb90e61

Условия реакции

Подробные условия
See reaction.notes.procedure_details.

Обработка

  1. 1
    ФильтрацияAfter hydrogenation and filtration over "Celite" (Trade Mark)
  2. 2
    Фильтрацияfilter aid
  3. 3
    Экстракцияthe filtrate was extracted twice with 20 ml portions of diethyl ether
  4. 4
    КонцентрированиеThe aqueous phase was concentrated by evaporation under reduced pressure
  5. 5
    Другоеthe residue was purified by chromatography through a Lobar column (Merck "LiChloprep RP-8", size B, two columns)
  6. 6
    Промывкаeluted with 2% aqueous methanol

Методика

The procedure of Example 1(3) was repeated, except that 100 mg of p-nitrobenzyl (1R,5R,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-oxo-1-carbapenam-3-carboxylate and 90 mg of 2-(4-methyl-3-oxopiperazin-1-yl)-2-iminoethylmercaptan hydrochloride were used. After hydrogenation and filtration over "Celite" (Trade Mark) filter aid, the filtrate was extracted twice with 20 ml portions of diethyl ether. The aqueous phase was concentrated by evaporation under reduced pressure, and the residue was purified by chromatography through a Lobar column (Merck "LiChloprep RP-8", size B, two columns), eluted with 2% aqueous methanol, to give 10 mg of the title compound.

Источник

DOI: 10.6084/m9.figshare.5104873.v1Патент: US04771046uspto-grants-1988_09